Recent Updates — TKNO

Alpha Teknova priced an underwritten public offering of 8,000,000 shares of common stock at $5.00 per share, generating gross proceeds of approximately $40 million before deducting underwriting discounts and commissions. The company granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares. Net proceeds are intended for general corporate purposes, including potential debt repayment. The offering is expected to close on or about October 22, 2026. Alpha Teknova manufactures critical reagents and media for the life sciences industry.

Alpha Teknova reported second quarter 2026 total revenue of $12.2 million, an 18% increase from the prior year's $10.3 million, driven by growth in both Lab Essentials ($9.2 million) and Clinical Solutions ($2.4 million). The company raised its full-year 2026 revenue guidance to a range of $45-47 million and adjusted its Free Cash Outflow expectation downward to less than $8 million. Net loss narrowed to $3.2 million, or negative $0.06 per diluted share, compared to a net loss of $3.6 million in the same period last year. Gross margin improved to 40.1% from 38.7%, while operating expenses rose to $7.8 million due to increased sales and marketing headcount. The company launched its AI-powered Build-Tek custom order configurator and ended the quarter with $17.4 million in cash and short-term investments against $13.2 million in borrowings. Alpha Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics.